Physician profile
Crystal Brown
NPI 1245763937
$4,698.51
in general payments reported to CMS, 2019-2025
33 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $947 · 2022: $695 · 2023: $834 · 2024: $1,181 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,056.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $582.88 | 2021-2024 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $472.30 | 2021-2024 | Glassia, Hyqvia, Cuvitru |
| Gilead Sciences, INC. | $453.99 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $358.68 | 2025 | Dovato, Cabenuva |
| Inari Medical, INC. | $294.74 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Grifols USA, LLC | $283.14 | 2021-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $247.42 | 2021-2025 | Dupixent |
| Electromed, INC. | $191.63 | 2021-2024 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $181.93 | 2021-2024 | Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.08 | 2021-2024 | |
| Novo Nordisk INC | $180.63 | 2021-2024 | |
| Insmed, INC. | $174.25 | 2021-2023 | Arikayce |
| Mallinckrodt Hospital Products INC. | $168.24 | 2021-2024 | Acthar |
| Alnylam Pharmaceuticals INC. | $121.84 | 2024 | Amvuttra |
| Abbvie INC. | $121.80 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $91.72 | 2025 | Egrifta |
| Lilly USA, LLC | $77.98 | 2021-2023 | Trulicity, Mounjaro |
| United Therapeutics Corporation | $66.24 | 2022-2024 | Tyvaso |
| Pulmonx Corporation | $57.70 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Axsome Therapeutics, INC. | $52.87 | 2022-2023 | Sunosi |
| Jazz Pharmaceuticals INC. | $52.33 | 2021 | |
| Genzyme Corporation | $45.98 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $39.46 | 2021-2022 | |
| Mylan Specialty L.P. | $32.12 | 2021 | |
| Genentech USA, INC. | $27.64 | 2022 | |
| Smith+Nephew, INC. | $23.56 | 2022 | |
| Csl Behring | $20.67 | 2022 | |
| Merck Sharp & Dohme LLC | $18.39 | 2023 | Belsomra |
| Advanced Respiratory, INC | $17.66 | 2021 | |
| Glaxosmithkline, LLC. | $17.57 | 2023 | Trelegy Ellipta |
| Ani Pharmaceuticals, INC. | $15.79 | 2023 | Purified Cortrophin Gel |
| Baxter Healthcare | $15.59 | 2022 | |
| Inogen, INC. | $10.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.